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Abstract
Background: Clinical trials evaluating interventions for infectious diseases require enrolling
participants that are vulnerable to infection. As clinical trials are conducted in increasingly
vulnerable populations, issues of protection of these populations become challenging. In settings
where populations are forseeably oppressed, the conduct of research requires considerations that
go beyond common ethical concerns and into issues of international human rights law.
Discussion: Using examples of HIV prevention trials in Thailand, hepatitis-E prevention trials in
Nepal and malaria therapeutic trials in Burma (Myanmar), we address the inadequacies of current
ethical guidelines when conducting research within oppressed populations. We review existing
legislature in the United States and United Kingdom that may be used against foreign investigators
if trial hardships exist. We conclude by making considerations for research conducted within
oppressed populations.
Background
There is an overarching assumption that medical research,
in general, is a good thing. Even those who don't sub-
scribe to this arguably simplistic view would hold that
medical research is absolutely necessary. This situation is
made complex by a widespread expectation that science
and technology are expected to be capable of curing all
conditions. Society and the medical community have
come to the conclusion that research on humans is both
necessary and desirable. This poses urgent questions,
however, when we consider the poor quality and poor
outcomes of most clinical trials and basic science experi-
ments [1-7] As clinical trials and sentinel data expand in
number and location, the necessity and relevance of
research's worth to participants represents both an ethical
and human rights concern [8]. The recent globalization of
international clinical trials highlights relatively new ques-
tions as to whether conducting research in marginalized
or oppressed populations can or should be acceptable.
The number and breadth of international and regional
instruments displays the lack of clarity that exists within
the biomedical fields of research. Declarations, by their
very nature, are non-binding instruments that guide the
conduct of research, but may hold mandatory rules within
single institutions, not inter-state. Some have asserted that
part of the problem is not that there is too little interna-
tional standard setting but that there is too much of it [9].
We believe that issues arising in clinical trials are not lim-
ited to ethical concerns, but at times enter the world of
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further discussion and the difficulties of conducting inter-
national research and the complexities of contemporary
medical research in the developing world, particularly
research amongst populations that are known to suffer
systematic human rights violations- from here on called
'oppressed'. We recognize that in-light of existing cases of
participation in rights and ethics violations, any new dec-
larations or legal instruments must have the requisite
teeth to bite when transnational companies and sovereign
states engage in questionable foreign research with fore-
seeable negative consequences.
We have previously addressed the role of researchers in
promoting vulnerable population participant rights in
respect to HIV clinical trials [10]. Here, we present an
overview of considerations for the conduct of research,
whether clinical trials or sentinel data collection, when
working with systematically oppressed populations.
Using case-examples from Thailand, Nepal, and Burma
(Myanmar), we recommend considerations regarding the
protection of participants and local colleagues in settings
with oppressed populations.
Thailand
Conducting trials within a population that is not just mar-
ginalized but is actually under direct threat from govern-
ment action poses its own problems for researchers. The
situation concerning those involved in the drug trade in
Thailand remains of grave concern. During Thailand's
2003 'war on drugs,' over 2,500 alleged drug traffickers
and users were extrajudicially killed [11]. The former
Prime Minister, Thaksin Shinawatra (since ousted in a
bloodless coup), publicly denigrated non-government
organizations for reporting the human rights abuses inter-
nationally [12].
Given these conditions, conducting research that collabo-
rates with Thai authorities and addresses drug user issues
creates dilemmas that straddle ethics and international
human rights law. Could participation in a state-author-
ized clinical trial of HIV prevention 'out' an intravenous
drug user and potentially expose them to a risk of state-
sanctioned violations? In these circumstances, what duties
regarding privacy and confidentiality of information exist
on the part of the researcher? Although medical records in
a clinical trial are confidential, the security of the records
is a serious concern, given the state history of behavior
amongst this population. It is not unreasonable to suggest
that lists of populations can be used to devastating effects
when we consider the state-led violence in Rwanda's gen-
ocide, Chile's military rule, or China's crack-down on
Falun Gong membership [13,14].
A clinical trial that is currently being conducted in Bang-
kok amongst IDUs displays the complexity and challenges
that exists when one examines clinical trials only as an
ethics dilemma or only as a legal dilemma [10]. The trial,
assessing the effectiveness and safety of oral tenofovir for
HIV prevention in 1,600 IDU participants from the Bang-
kok area, is funded by the US Centers for Disease Control
and prevention (CDC) and conducted by Thai research
partners. This trial, like others around the world assessing
tenofovir, has come under scrutiny for highlighting ethi-
cal questions rarely addressed. In this case, the study is
funded by a US state transnational organization. US state
funds are not permitted to cover the supply of drug para-
phernalia and as a result, clean needles are not provided
to participants. However, article 29 of the Helsinki Decla-
ration states that 'benefits, risks, burdens and effectiveness of
a new method should be tested against those of the best current
prophylactic 'interventions [15]. Further, article 23 of the
recent UNGASS Declaration of recommitment to HIV/
AIDS, signed by both Thailand and USA [16], notes the
affirmation of access to essential commodities, including
sterile injection equipment and harm-reduction efforts
related to drug use. This raises important legal and ethical
concerns. Domestic laws, such as the US policy, are coun-
tered by international norms for provision of clean nee-
dles [16]. Should a foreign state's (US) laws override an
internationally agreed upon standard of clinical trials, the
Helsinki Declaration or the UNGASS Declaration, signed
by both the Thai and United States Medical Associations?
Nepal
In autumn 1995, the United States Armed Forces Research
Institute of Medical Sciences established the Walter Reed/
AFRIMS Research Unit-Nepal field unit in Kathmandu,
Nepal, for the study of Hepatitis E, a water-borne disease
with a high maternal mortality rate.
In late 1999, plans for a Phase II/III clinical trial of a Hep-
atitis E vaccine were approved by the Nepal Health
Research Council and the U.S. Army's Human Subjects
Research Review Board[17]. The vaccine had been pat-
ented by California based biotech company Genelabs,
and licensed by SmithKline Beecham (now GlaxoSmithK-
line). It was subsequently announced that the trial would
begin in mid February 2000 with the screening of 8,000
volunteers in Lalitpur, 3,000 of whom would be enrolled
in the trial receiving the vaccine or placebo. Following the
trial's announcement Genelabs' share price nearly dou-
bled, reaching their highest level in the nine year history
of the company [18]. While shareholders were celebrating
their good fortune, articles began to appear in Nepali
newspapers suggesting that the Nepali population was
being taken advantage of by Western pharmaceutical
companies. Concerned about the controversy and possi-
ble political fall-out, local government officials from Lal-Page 2 of 10
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should not continue as scheduled until the researchers
satisfied the governing committee that relevant actions
such as post-trial access had been accomplished.
During this intermission, the controversy heightened,
with critics asking whether there had been adequate edu-
cation to allow informed consent among the trial partici-
pants and why researchers would not contribute to the
clean up the water supply – Thailand had been initially
planned as trial site but the disease had been largely erad-
icated in the 80's and 90's due to advances in water sani-
tation. The Deputy Mayor had asked for a hospital to be
built, as proposed profit sharing was considered out of the
question. The prohibition against the trial was upheld and
it was moved to a community that predictably did not
raise any objections: recruits from the Royal Nepalese
Army.
As with any army population, the use of serving members
of the military as trial participants is dubious at best since
questions of informed consent and undue influence must
be asked in light of what is necessarily a highly ordered
and authoritative community, even in developed nations
[19]. Upon entering military service, soldiers necessarily
give up certain rights enjoyed by private citizens and it is
conceded that if a military is to be at all effective there
must be some element of the destruction of individual
autonomy. However, can there consistent informed con-
sent in the RNA when there is only 44% literacy rate? [18]
Nepal's military is also well known for torture, disappear-
ances and inadequate and infrequent pay for its members
[20]. Can conscripts ever be said to engage in any military
activity voluntarily? How much coercion is involved by
decision-makers? Can a participant withdraw? [21] When
Sachit Rana, Chief of Army Staff at the RNA, claims "the
army can do anything it wants – shoot at people, use
bombs, arrest people" [22], it is difficult to imagine a
more unsuitable population for such a trial. Surely insti-
tutions that are guilty of mass human rights abuses, such
as the RNA or the Thai drug authorities, should be neither
subjects nor partners for human subject research, yet in
this case they were both – a sad state of affairs seeing as the
trial had been approved by the National Institute of
Allergy and Infectious Diseases and US Army IRBs.
Burma (Myanmar)
In the examples of Thailand and Nepal, we present cases
of clinical research that could have been conducted in
populations other than the oppressed participant popula-
tions. However, should research ever be conducted in
populations with foreseeable oppression?
There are few countries in the world that can boast of such
egregious human rights violations as Burma (Myanmar).
A military government, since 1958, has ruled Burma. In
1988, a new military government, the State Law and
Order Restoration Council (SLORC) took over and
renamed the country Myanmar. SLORC would change
Burma's name to Myanmar and impose martial law,
repressing any democracy movements [23]. SLORC
would begin a systematic train of human rights abuses
including forced labour, rape, torture and murder [24].
Burma's present authoritarian military government, the
State Peace and Development Council (SPDC), continues
to operate a strict police state and drastically restricts basic
rights and freedoms. Its military is estimated at 350,000
and as many as 70,000 are estimated to be child soldiers
[25,26]. Freedom of expression, assembly, and associa-
tion are not respected and the arbitrary detention and
incarceration of those expressing their political opinions
continues [26]. As a result of the military violations, the
United Nations appointed a country specific Special Rap-
porteur on the situation of human rights Myanmar since
1992. Most recently, the Doe versus Unocal case set impor-
tant precedent [23]. This case, settled in 2005, addressed
whether Unocal, a multinational oil company, could be
held responsible for crimes against humanity committed
by the Myanmar military, a business partner. The case was
found admissible and demonstrates that multinational
companies that partner with repressive states may be
responsible for their partnering states actions. Given the
widespread nature of the human rights violations, it is dif-
ficult to determine whether researchers should choose to
conduct their work in such an atmosphere. We recognize
that even in vulnerable populations, relevant research is
necessary if the population has exception medical needs,
as in the case of malaria, which is often geographically dis-
tinct in terms of drug-resistance and endemicity [27]. This
may explain why so many malaria trials have been con-
ducted in Burma.
When dealing with geographically specific diseases, we
need to consider the importance of the research initia-
tives. Trials evaluating artesunate treatment for malaria
have been successfully conducted in Burma amongst mil-
itary recruits and their families. These clinical trials,
approved by the University of Oxford ethics review com-
mittee in the UK, display the inadequacy of our current
ethics frameworks. Regardless of actual human rights vio-
lations within the trial, it seems implausible that the eth-
ics review committee members from Oxford have a
through knowledge of the situation for Burmese recruits
residing in Burma. The Oxford review committee insisted
on a partnership between the Oxford researchers and the
SPDC Ministry of Health (MOH). At this time it is worth
noting the debacle last year between the SPDC and the
Global Fund to Fight AIDS, TB, and Malaria resulted in the
withdrawal of funding for HIV/AIDS programmes as the
junta had prevented allocation of resources to thePage 3 of 10
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for military purposes instead [28].
Given the realities of research infrastructure, clinical trials
conducted in Burma must partner with the relevant local
authorities. These trials raise important and difficult ques-
tions. As illustrated in the Doe vs Unocal case, partnering
with the Burmese government is against many state laws
and may implicate a research body in crimes. We would
argue that partnering with such an organization may be
excusable in limited circumstances – where there are com-
pelling and pressing reasons why such research cannot be
conducted amongst another population. Indeed, several
trials demonstrating the effectiveness of artesunate based
therapies for severe malaria have instigated a national pol-
icy change regarding treatment within Burma, demon-
strating that this research was necessary and in certain
circumstances can result in important improvements for
the populations at risk [29].
Discussion
These case studies illustrate the complexities and potential
pitfalls of examining research from simply an ethical or
simply a human rights legal framework. As previously
stated, there are many international instruments that con-
fer and safeguard the rights of participants in clinical tri-
als. The first widely-adopted instrument was the
Nuremburg Code; followed in 1964 by the Helsinki Dec-
laration (since revised 7 times by the World Medical Asso-
ciation) [15]; the 1966 International Covenant on Civil
and Political Rights (CCPR)(particularly Article 7 as it
relates to consent for medical and scientific experiments)
[30]; the Council for International Organizations of Med-
ical Sciences (CIOMS) international ethical guidelines in
1993 (since revised) [31]; and, the 1996 International
Conference on Harmonization of Technical Require-
ments for Registration of Pharmaceuticals for Human Use
– Good Clinical Practice: Consolidated Guidelines [32].
On a European level [EU], the EU has issued its directive
on good practice in clinical trials [33] and the Council of
Europe has issued a Convention on Human Rights and
Biomedicine on biomedical research [34]. Most recently,
UNESCO has developed a Universal Declaration on
Bioethics and Human Rights [35]. Although there is con-
siderable overlap between these documents there are also
dramatic differences between them, that no doubt con-
tribute to general confusion and the possible conflation of
discrete legal principles that has resulted in some pausing
to question whether they can contribute to the develop-
ment of a comprehensive international framework [9].
Given their brevity, the Nuremberg Code and the CCPR
are of minimal benefit today in any discussion on human
rights in clinical trials. Neither document recognizes the
distinction between therapeutic and non-therapeutic
research. This fundamental deficiency means that they
have largely been ignored by the medical profession. A
logical consequence of a strict construction of Article 1 of
the Code and Article 7 of CCPR (both addressing consent)
would mean that consent would be necessary in all cir-
cumstances: those who become unconscious due to an
accident or disease or those who are mentally handi-
capped could not, if no standard treatment exists, be
offered new therapeutic measures that might restore their
health or save their lives. Such a rigid interpretation would
mean that the respective provisions exclude many of those
they were designed to protect. Furthermore, in the case of
Article 7 CCPR it is obvious that the provision is to be read
as a whole and that the caveat contained in the second
sentence must be read in conjunction with the first.
"No one shall be subjected to torture or to cruel, inhuman
or degrading treatment or punishment. In particular, no
one shall be subjected without his free consent to medical or
scientific experimentation."
The Article prohibits experiments that violate the integrity
of the person by cruel, undignified or inhuman treatment.
Clinical research carried out in accordance with general
principles would not violate this provision. Yet the right
to health argument confounds this. At the recent XVI
International AIDS Conference in Toronto, UNAIDS pre-
sented an ethical argument as to why trial participants that
seroconvert during a trial do not require access to effective
treatment [36]. UNAIDS representatives considered these
ethical and not obligatory legal issues. We were dumb-
founded to see a UN agency using an ethical argument to
abstain from providing the highest attainable standard of
health, a human right guaranteed in so many UN legally
binding documents.
Although the ethics declarations themselves are not bind-
ing legal documents, they arguably represent customary
law – law based on an established pattern of behaviour
that can be objectively verified within a specific field. The
Declaration of Helsinki is a respected document of long
standing and esteemed pedigree that is cited in numerous
international and national legal instruments, giving it
force of law in certain jurisdictions and under certain well-
established principles, such as voluntary participation and
informed consent [37]. It is signed by all member-state
medical associations. It is also subject to intermittent revi-
sions approved by the General Assembly of the World
Medical Association (WMA), and therein lies its vulnera-
bility: the WMA is a non-governmental association and is
subject only to private law while the rights of participants
in clinical trials is increasingly being viewed through the
prism of international human rights law [37]. There is lit-
tle recourse for most Nepali rural dwellers or drug users
who might have participated in a trial that conceivablyPage 4 of 10
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(access to effective interventions) or the RNA conscript
whose participation is, on first appearance, a violation of
Article 20 (informed and voluntary consent) if there has
not been ratification by their respective national legisla-
tures.
This shortcoming is even more pronounced with respect
to the CIOMS since the method by which proposals are
adopted is much less transparent. It was the covert nature
of the deliberations that led some to criticize the 1993 ver-
sion of the guidelines claiming that protection had been
over emphasized and more pragmatism had been called
for, reflecting much more the interests of the research
community than the basic rights of the individual or offi-
cial WHO policy [38]. However, the 2002 CIOMS guide-
lines do make reference to the Declaration of Helsinki and
indeed claim it is "the fundamental document in the field of
ethics in biomedical research."[31] The updated version also
enunciates the laudable goal that "the research is responsive
to the health needs and the priorities of the population or com-
munity in which it is to be carried out; and any intervention or
product developed, or knowledge generated, will be made rea-
sonably available for the benefit of that population or commu-
nity."[39]' Nevertheless, as stated in the Declaration of
Helsinki, human rights issues are coming to be seen as
within the proper domain of public law and private law
remedies such as negligence and the tort of trespass do not
constitute a potent deterrent for unscrupulous researchers
operating in under-developed countries where access to
legal advice is scarce and/or prohibitively expensive. But if
the long arm of civil law can reach them in their largest
market there may be light at the end of the tunnel.
Alien Tort Claims Act
One potentially powerful tool in the rebalancing of rights
within clinical trials in vulnerable populations is the
United States' Alien Tort Claims Act [ACTA, 28 U.S.C.,
1350] [40]. Considering that the majority of clinical trials
conducted in developing nations are supported by US
based organizations [5,41], the ATCA is particularly rele-
vant. It was originally part of the Judiciary Act of 1789 and
was one of the first laws of the new American Republic. A
federal law, it allows lower courts to hear cases in viola-
tion of international law or the "law of nations". There have
been 3 modifications since its passing and now reads:
"The District Courts shall have original jurisdiction of any civil
action by an alien for a tort only, committed in violation of the
law of nations or a treaty of the United States." The statute
had been invoked only five times in the first 200 years of
its existence and was arguably a rather ineffective remedy
[42]. There is renewed interest in the use of the tort as a
tool for human rights litigation. One of the most impor-
tant ATCA decisions, in 1980, the Second Circuit court
addressing Filartiga v. Pena-Irala [43], held that the ATCA
represented liability for torture committed using state
authority as it found a Paraguayan police official that vis-
ited the US to be criminally responsible for his actions in
torturing and disappearing a young man in Paraguay. Tor-
ture, in this case, was viewed as illegal under any interna-
tional circumstances as no reasonable state should permit
torture. In 1995, the tort was used to serve Radovan Kara-
dzic for atrocities in Bosnia in the Kadic v. Karadzic [44]
case, that expanded the statute's reach to private actors.
These decisions put to rest (at least on the Second Circuit)
questions regarding whether or not the Act conferred mere
jurisdiction or an actual substantive cause of action [45].
It should be noted, however, that ATCA does not grant the
federal courts jurisdiction over foreign governments or
their agencies [46]. Nevertheless, it is clear now from a
developing body of case law, and the recent case of Doe I
v. Unocal Corp, a case that identified Unocal Oil Corpora-
tion responsible for atrocities committed in partnership
with the Burmese junta, that the liability of multinational
corporations falls squarely within the domain of ACTA.
Most recently, in 2007 US Federal Prosecutors used the
ATCA successfully against Chiquita Brands International
for their funding of Colombian rebel groups resulting in
fines [47].
For a claim to be successful under ATCA there are three
requirements: (i) there must be alien plaintiffs; (ii) suing
for a tort; (iii) committed in violation of international law
[24]. The first two required elements are relatively
straightforward; however, the third presents difficulties as
it requires American courts to consider customary interna-
tional law or treaties and attempt to give effect to custom-
ary law, where actual law had not previously existed. This
task is simplified somewhat if the alleged violations con-
cern international laws that are jus cogens – a violation of
international norms from which no derogations are per-
mitted. The Unocal case concerned forced labour which
was likened to slavery – a blatant jus cogens violation.
However, the court held that "a jus cogens violation is suf-
ficient, but not necessary, to state a claim under the ATCA"
[23]. With this in mind there is an argument to be made
that a violation of a provision of the Helsinki Declaration
resulting in foreseeable injury could found a claim under
ATCA. Might a conscript in the Burmese Army or the
Royal Nepali Army file a suit against SEAQUAMAT or
GlaxoSmithKline respectively for their part in a trial alleg-
ing a lack of informed consent and therefore an infringe-
ment of Article 20 of the Declaration of Helsinki? Could
the family member of a Thai IDU who was subject to
extrajudicial execution sue a pharmaceutical corporation
for retaining a Thai police officer as security by alleging a
violation of the victim's right to confidentiality as
expressed by Article 21?Page 5 of 10
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extent, when the State of New York Federal Court permit-
ted a Nigerian claim against a multinational pharmaceuti-
cal company, Pfizer Ltd, for the conduct of therapeutic
research using an experimental antibiotic, Trovan, versus
the on children without receiving informed consent dur-
ing a meningitis epidemic in Nigeria [48]. In this clinical
trial (n = 200), 11 children died and others were left blind
or paralyzed. This case was dismissed from the US courts
in 2002, finding on the grounds of that the case be com-
pleted in Nigeria, where able courts exist (forum non con-
veniens), but did identify Pfizer US as a state-actor, given
its financial inter-dependence with the US government,
and the approval of the US Food and Drug Administration
for the trial. In Nigeria, criminal charges have been
brought against Pfizer officials and a civil suit seeking bil-
lions in damages has been sought. The case is ongoing.
On June 29, 2004, in the case of Soza vs Alvarez-Machain
[49], the US Supreme Court upheld the ATCA in recogni-
tion of serious human rights abuses. The court did how-
ever, limit these abuses to "specific, universal, and
obligatory international norms (violations of safe con-
duct, infringement of the rights of ambassadors)." Never-
theless, courts may not be slow to accept new causes of
action under ATCA as recent decisions on the concept of
complicity and secondary liability differ. ATCA claims are
generally held against private organizations that may be
working independently or as state-actors. However, it can-
not be applied to the state itself. In the Thai and Nepali
trial examples, the trials were funded by the US state, with
some involvement however peripherally with the drug
manufacturer. The New York District Court has held that
liability in international law "for knowing practical assist-
ance or encouragement which has a substantial effect on
the perpetration of the crime" is a core principle that
forms the foundation of customary international legal
norms [50]. Only time will tell which approach is ulti-
mately adopted.
The arguments laid out towards the use of the ATCA and
United Nations Global Compact [51] on good corporate
responsibility are limited as they apply predominantly to
multinational corporations and not to states. However,
states are the largest funders of clinical research on
neglected diseases in developing settings and in all case
examples that we apply here, states have either funded or
coordinated the clinical research. There are state laws
regarding state behaviour when dealing with oppressive
regimes. Without being extensive, we briefly describe rel-
evant laws in the United States and the United Kingdom.
502B
The US government has issued communications to sitting
judges claiming that ATCA should be given a narrow inter-
pretation, arguing in support of limiting the role of ATCA
to finding corporations liable for human rights violations.
Such conduct should be seen in light of existing legisla-
tion designed to prevent the government from trading
with known human rights abusers. Section 502B of the
Foreign Assistance Act of 1961 (now coded as 22 U.S.C.,
2304) as amended reads "...a principal goal of the foreign
policy of the United States is to promote the increased observ-
ance of internationally recognized human rights by all coun-
tries." The law enforces that no state-funds made available
by the Foreign Assistance Act should be dispensed to for-
eign military units with known human rights violations
for weapons or training. In the spirit of the law, the provi-
sion of funding to Thai military or Nepali military seems
specious. Although the statute addressing defense appro-
priations allows for derogation if such action is certified
by the Secretary of State owing to "extraordinary circum-
stances", it is difficult to see why the jurisdiction of the US
courts should be denied to victims of a corporate-foreign-
regime-relationship when such a regime would not even
qualify for US foreign aid by virtue of them being known
human rights violators. This law, commonly known as the
Leahy Law (after Senator Patrick Leahy) has most
famously been implemented with regards to assisting spe-
cific units in Colombia's military, which was circum-
vented by units swapping out abusers to make specific
units clear of abusers.
United Kingdom
There is not one exhaustive statute that deals with prevent-
ing government and the private sector partnering with
rogue states or abusers of human rights. The UK has
passed a number of statutes that authorize the imposition
of trade or economic sanctions, providing some inference
that illegal behaviour outside the UK is viewed with con-
demnation.
The United Nations Act 1946
This Act is essentially an enabling statute that brings UN
Security Council resolutions into the law of England and
Wales. Once again, under Chapter VII (Article 41) of the
United Nations Charter, if the UN Security Council deter-
mines that a threat to the peace, a breach of the peace or
an act of aggression has occurred, it may decide what
measures shall be taken to maintain or restore interna-
tional peace and security. A UN Security Council decision
taken pursuant to Article 41 imposes a legal obligation on
the UK (as a UN Member) to take all necessary measures
to give effect to the decision domestically. When a resolu-
tion imposes sanctions, the UK must introduce them into
domestic law. This is done by passing statutory instru-
ments under the United Nations Act.
Section 1(1) of the Act enables Parliament to pass legisla-
tion in furtherance of Article 41. It provides:Page 6 of 10
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His Majesty's Government in the United Kingdom to apply
any measures to give effect to any decision of that Council,
His Majesty may by Order in Council make such provision
as appears to Him necessary or expedient for enabling those
measures to be effectively applied..."
The UN Security Council resolution will be enabled in
domestic law by way of an Order in Council (a statutory
instrument) made by the Foreign Secretary, and laid
before Parliament. Such an instrument will have force of
law and a violation of it could bring a term of imprison-
ment of up to 6 years.
Recent example of Orders in Council made under the Act
include: The Sudan (United Nations Measures) Order
2006 [52]; The Lebanon and Syria (United Nations Meas-
ures) Order 2005 [53]; The Democratic Republic of the
Congo (United Nations Measures) Order 2005 [54].
These Orders in Council are simply a mechanism by
which UN Security Council resolutions are enacted and
made enforceable in the UK under domestic law. They do
not proscribe trade or aid with nations or organisations
who are not subject to a Security Council sanction and
who may be gross human rights violators. Further, they do
not forbid all trade even with proscribed countries but
only those items specified in the Security Council resolu-
tion (most often arms, aircraft, etc.).
The Export Control Act 2002
The Import, Export and Customs Powers (Defence) Act 1939
provided the Secretary of State with a general power to
impose import and export controls on goods. The 1939
Act was considered to be a temporary measure to deal
with the emergencies of the time. However, the 1939 Act
has remained in force (although it was amended by the
Import and Export Control Act 1990 to allow it to con-
tinue in force without relying on the continued existence
of "the emergency" that existed in 1939).
The Scott Inquiry into Export of Defence Equipment and
Dual-Use Goods to Iraq and Related Prosecutions in February
1996 identified a number of limitations in the 1939 Act,
including the lack of parliamentary scrutiny of secondary
legislation made under the Act and the absence of any
indication of the purposes for which export controls may
be imposed. The 2002 Act was passed after a government
white paper was circulated that took account of some of
the concerns raised by Lord Scott.
In the absence of a UN Security Council resolution embar-
going trade with a particular group or nation, the UK has
the power to prohibit such trade by use of Orders in
Council made under the Export Control Act 2002. But are
clinical trials a trade issue? Section 5(2) of the Act states
that " [c]ontrols of any kind may be imposed for the pur-
pose of giving effect to any Community provision or other
international obligation of the United Kingdom." This
refers to bilateral and multilateral agreements which the
UK may have, notwithstanding their UN obligations. In
practice it is most common for Orders in Council made
under the Act to be in furtherance of European Union
objectives, an example being under Title V of the Treaty on
European Union (provisions on a common foreign and
security policy).
Although there is guidance from the EU on trading and
engaging with rogue states (for instance the European
Union Code of Conduct on Arms Exports) the regulations
are not all-encompassing. Matters of defence and foreign
policy are still within the proper domain of member states
and since both of these areas are governed to a large extent
in the UK by the Royal Prerogative it is not difficult to see
instances where partnering with questionable regimes
would be possible since it had not been specifically pro-
scribed by the EU.
The power of US 502B is that it requires the Secretary of
State to justify why trade/aid should be allowed with such
a nation despite its hideous human rights record. Whether
or not 502B has had a positive impact on foreign trade
and the ability to partner with rogue regimes is difficult to
say, since exemptions can be made under it if they are cer-
tified by the Secretary of State. Although this is not an
ideal safeguard, it does force politicians to publicly
declare the reasons for partnering with such a regime.
Considerations for the Conduct of Research within 
Oppressed Populations
As the costs of research increase it is no wonder that phar-
maceutical companies are looking to developing nations
to conduct much of their research. Much of the marketing
of multinationals is now trumpeting their commitment to
human rights and the environment. Indeed many of the
world's largest companies have apparently embraced
guidelines drawn up by the United Nations concerning
ethical conduct, such as the UN Global Compact and the
UN Norms on the Responsibilities of Transnational Cor-
porations and Other Business Enterprises with Regard to
Human Rights [55]. Yet in the same breath these compa-
nies are lobbying in Washington in an attempt to have the
Alien Tort Claims Act repealed by propagating the fiction
that it will make it impossible for well-intentioned com-
panies to know what conduct might subject them to lia-
bility or that it will stifle foreign investment. It is not
cynical to suggest that this is the case because the Global
Compact and the UN Norms do not contain a word about
enforcement.Page 7 of 10
(page number not for citation purposes)
Globalization and Health 2007, 3:10 http://www.globalizationandhealth.com/content/3/1/10It is evident that in the absence of any effective interna-
tional legal framework to address the dilemmas and com-
plexities of research in vulnerable populations we are set
to see the further abuse of human rights. Table 1 lays out
necessary considerations for the conduct of clinical
research in oppressed populations. It must be the case that
if companies or states are going to reap the benefits of
conducting research on vulnerable groups they carry out
they requisite appropriate consultation. Ethical review
boards cannot be a 'one size fits all' but must take into
account local concerns and address those concerns in liai-
son with local representatives and further in-roads must
be made into the entrenched hostility on the part of drug
companies to post-trial medical care. The greater the
atmosphere of vulnerability the greater the level of consul-
tation must be; in settings with foreseeable human rights
violations, such violations much be captured. The time is
ripe for an international legal instrument to address these
concerns and upon ratification in national legislatures to
provide a substantive cause of action without excessive
restrictions on locus standi which result in companies
never being brought to book as 'victims' never make it to
court. These are complex issues that demand attention,
and in the absence of an international convention, it falls
to creative and bold jurists to push for these issues in
courts of law and various international fora.
Table 1 highlights issues for consideration of the conduct
of oppressed populations. We have previously listed con-
siderations for conduct in difficult to protect populations,
and these previous recommendations are updated here.
These recommendations recognize that research is often
required within specific populations, but that research
should be health promoting, rather than risking placing
specific or large groups of a population at risk of violence,
detention, or other state-led abuses. While no list is
exhaustive and each setting is likely to be substantially dif-
ferent, these considerations address specific issues that are
applicable to oppressed populations, where the likeli-
hood of harm is impending. We predominantly argue that
where oppression exists, the argument for conducting
research in that population needs to substantially out-
weigh the negatives of not conducting the research. The
central argument is the optimal balance between ensuring
the safety of participants while advancing the needs of sci-
ence. The "intentionality" of the research endeavour
should not only be to advance scientific knowledge but
also offer practical benefits, or at least the hope of future
benefits for the oppressed population. Researchers need
to bear the burden of proof and strive to minimize coer-
cion. They need to identify representative leaders who rep-
resent the diversity of opinions, conduct public
deliberations in the spirit of participatory decision-mak-
ing and try to ensure decision making as much as possible
at the local level. Some authors argue for a " modus viv-
endi " approach that favours decision-making via com-
promise rather than rational consensus. As we alluded to
at the beginning of this paper, the assumption that
Table 1: Considerations for conducting research in oppressed populations
Health Promoting For clinical effectiveness interventions, interventions should be health promoting and address a clearly 
population relevant illness. There should be a clear plan for how research findings will assist community, 
based on a priori agreement on how findings will be used. This requires active engagement with target 
groups and plans for how findings should be interpreted with target group members.
Opportunities to avoid exposures 
should be afforded to participants
Exposures may include exposures to the target diseases or to human rights violations. This should include 
education (e.g. condom use, needle provision and needle cleaning); assistance with known human rights 
promoting activities or possible escape; and, the avoidance of remaining in exposed status.
Planned efforts to determine the 
human rights status of a particular 
population
This may include formative research and background reviews of human rights NGO literature.
Community participation 
commensurate with level of political 
oppression
There are few reliable ways to measure oppression. Due to the large geographical and cultural 
heterogeneity, there may not be a unified voice and so we need minimum standards for Community 
Advisory Boards (CABs).
CABs must include mixed levels of 
education, oppressive situations, age 
and gender
They should be able to inform on the importance of the research and therefore, acceptability. CABs may 
need to be outside target areas (i.e. Burma)
The more oppression, the more 
reason for research required
Assuming researchers cannot improve oppressive setting, the conducting research may be placing 
participants or colleagues at risks. Oppressive conditions may make population 'captive'
HR violations should be captured Good research captures all health outcomes determined of interest in clinical event forms. In certain 
conditions we can anticipate HR violations. Case report forms should inquire of HR violations. This may 
allow for subgroup analyses.
Report an Ethical methodology Ethics and human rights issues are not black or white issue (ethical or not ethical), but require explanation 
to determine challenges that exist in the research settings. It may well be appropriate to advocate for a 
limitations section of the article that addresses what could not be accomplished. This could be advocated by 
the Consolidated Standards for Reporting of Randomized Trials Group (CONSORT), a group that 
advocates minimum standards of reporting clinical research. It is only through acknowledgement of these 
issues that the field can be advanced.
Measure long-term impact, for 
informing "customary research"
We need to determine if the research has improved conditions, or worsened it? Has 'Western' research 
improved or reduced the quality/expectations of indigenous research? Finally, we need to determine if post-
trial access was accomplished and what care was provided for post-trial injuries related to participation.Page 8 of 10
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naïve and is not supported by evidence. Good intentions
alone are likely to be insufficient in protecting potential
participants and so extra caution and planning is required.
Conclusion
As the medical research world becomes increasing glo-
balized, there is a need to make research both methodo-
logically valid and culturally valid. In the examples that
we have highlighted, conducting research within
oppressed populations stretches the current norms of
medical ethics as well as stretching the current capabilities
of international law. To rely simply upon minimum
standards of non-binding and vague medical ethics instru-
ments for conducting research within these populations is
both naïve and culturally insensitive. Human lives are
inherently complex and no single ethical framework,
including ours can claim to capture the complexity of
research and understand the ethical dilemmas that arise in
these diverse settings. Paradoxically, legal course is least
available to oppressed populations where the need is
greatest. Ethical principals and legal approaches outlined
above are not intended to be rigid inflexible pillars, rather
as signposts along the way for researchers interested in
grappling with this challenge of conducting research
within vulnerable populations. In accordance with uni-
versal principals of justice, the "effective " participation of
oppressed populations in decision-making will be an
instrumental step in combating the social, economic and
political forces of globalization that constrain human
capabilities.
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